Fluorine in medicinal chemistry

被引:1401
作者
Böhm, HJ [1 ]
Banner, D [1 ]
Bendels, S [1 ]
Kansy, M [1 ]
Kuhn, B [1 ]
Müller, K [1 ]
Obst-Sander, U [1 ]
Stahl, M [1 ]
机构
[1] Roche, Div Pharmaceut, Discovery Res, CH-4070 Basel, Switzerland
关键词
basicity; fluorine; lipophilicity; metabolic stability; protein-ligand interactions;
D O I
10.1002/cbic.200301023
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Fluorinated compounds are synthesized in pharmaceutical research on a routine basis and many marketed compounds contain fluorine. The present review summarizes some of the most frequently employed strategies for using fluorine substituents in medicinal chemistry. Quite often, fluorine is introduced to improve the metabolic stability by blocking metabolically labile sites. However, fluorine can also be used to modulate the physicochemical properties, such as lipophilicity or basicity. It may exert a substantial effect on the conformation of a molecule. Increasingly, fluorine is used to enhance the binding affinity to the target protein. Recent 3D-structure determinations of protein complexes with bound fluorinated ligands have led to an improved understanding of the nonbonding protein-ligand interactions that involve fluorine.
引用
收藏
页码:637 / 643
页数:7
相关论文
共 50 条
  • [1] Carbonic anhydrase inhibitors: X-ray crystallographic structure of the adduct of human isozyme II with the perfluorobenzoyl analogue of methazolamide. Implications for the drug design of fluorinated inhibitors
    Abbate, F
    Casini, A
    Scozzafava, A
    Supuran, CT
    [J]. JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2003, 18 (04) : 303 - 308
  • [2] THE SYNTHESIS AND BIOLOGY OF FLUORINATED PROSTACYCLINS
    BARNETTE, WE
    [J]. CRC CRITICAL REVIEWS IN BIOCHEMISTRY, 1984, 15 (03): : 201 - 235
  • [3] *BIOB CORP POM COL, 2002, MEDCHEM DAT
  • [4] 1-substituted 4-aryl-5-pyridinylimidazoles: A new class of cytokine suppressive drugs with low 5-lipoxygenase and cyclooxygenase inhibitory potency
    Boehm, JC
    Smietana, JM
    Sorenson, ME
    Garigipati, RS
    Gallagher, TF
    Sheldrake, PL
    Bradbeer, J
    Badger, AM
    Laydon, JT
    Lee, JC
    Hillegass, LM
    Griswold, DE
    Breton, JJ
    ChabotFletcher, MC
    Adams, JL
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (20) : 3929 - 3937
  • [5] Bohm H.-J., 2006, PROTEIN LIGAND INTER, V19
  • [6] VAN DER WAALS VOLUMES + RADII
    BONDI, A
    [J]. JOURNAL OF PHYSICAL CHEMISTRY, 1964, 68 (03) : 441 - +
  • [7] To market, to market - 2002
    Boyer-Joubert, C
    Lorthiois, E
    Moreau, F
    [J]. ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 38, 2003, 38 : 347 - 374
  • [8] Small molecule interactions with protein-tyrosine phosphatase PTP1B and their use in inhibitor design
    Burke, TR
    Ye, B
    Yan, XJ
    Wang, SM
    Jia, ZC
    Chen, L
    Zhang, ZY
    Barford, D
    [J]. BIOCHEMISTRY, 1996, 35 (50) : 15989 - 15996
  • [9] Inhibitors of p38α MAP kinase
    Chakravarty, S
    [J]. ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 37, 2002, 37 : 177 - 186
  • [10] Structure-activity relationships of substituted benzothiophene-anthranilamide factor Xa inhibitors
    Chou, YL
    Davey, DD
    Eagen, KA
    Griedel, BD
    Karanjawala, R
    Phillips, GB
    Sacchi, KL
    Shaw, KJ
    Wu, SC
    Lentz, D
    Liang, AM
    Trinh, L
    Morrissey, MM
    Kochanny, MJ
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2003, 13 (03) : 507 - 511